Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.
The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.
House dust mite sublingual immunotherapy for allergic asthma (May 2016)
Injection allergen immunotherapy with house dust mite extract has demonstrated benefit in patients with asthma and house dust mite allergy, but is inconvenient and carries a small risk of serious allergic reactions. Sublingual immunotherapy tablets (SLIT-tablets) are a safer form of allergen immunotherapy with proven efficacy in allergic rhinoconjunctivitis, but studies in patients with allergic asthma are limited. In a randomized trial of over 800 house dust mite-sensitive adults with asthma not controlled by inhaled budesonide and short-acting beta-agonists, subjects were treated with house dust mite SLIT-tablets or placebo for 7 to 12 months, after which inhaled budesonide was gradually withdrawn and then stopped . House dust mite SLIT significantly prolonged the time to first moderate or severe asthma exacerbation, reducing the absolute risk of an exacerbation during budesonide withdrawal from 32 to 25 percent with placebo and SLIT, respectively. However, clinically meaningful improvements in other measures of asthma symptoms were not clearly demonstrated. Thus, further study is needed to assess the effectiveness of SLIT-tablets in patients with allergic asthma. HDM SLIT-tablets are not yet available in the United States, but are available in parts of Europe and in Japan. (See "Sublingual immunotherapy for allergic rhinoconjunctivitis and asthma", section on 'Moderate-persistent asthma'.)
New guidelines regarding the endocrine effects of long-term inhaled glucocorticoids in children (April 2016)
The Pediatric Endocrine Society Drugs and Therapeutics Committee released guidelines regarding adrenal insufficiency in children on long-term inhaled corticosteroids (ICS) . The guidelines recommend testing for adrenal insufficiency in children and adolescents who are taking long-term ICS (eg, >6 months) and have symptoms suggesting adrenal insufficiency (hypoglycemia, altered mental status, fatigue, weakness, anorexia, Cushingoid features, growth failure, or weight loss). The guidelines also suggest screening asymptomatic children and adolescents who are taking high-dose ICS. However, because of the rarity of clinically significant adrenal insufficiency, we prefer to follow an individualized determination of the need for screening, based on the presence of the following risk factors: >6 months' use of ICS at doses exceeding those considered "high," combined use of high-dose ICS and intranasal glucocorticoids or intermittent use of systemic glucocorticoids, and low body mass index (BMI) (eg, <15th percentile for age). The first step in screening for adrenal insufficiency is measurement of an 8 AM serum cortisol, followed by additional testing based on the result. (See "Major side effects of inhaled glucocorticoids", section on 'Children and adolescents'.)
A second monoclonal antibody against interleukin-5 approved for severe eosinophilic asthma (April 2016)
Reslizumab, a monoclonal antibody to interleukin (IL)-5, has been approved by the US Food and Drug Administration (FDA) for add-on maintenance therapy of severe asthma in patients who are age 18 or older and have an eosinophilic phenotype . It is similar to mepolizumab, which was approved in late 2015. In clinical trials of reslizumab, an eosinophilic phenotype was defined as a peripheral blood absolute eosinophil count ≥400/microL. Studies in patients with severe eosinophilic asthma have shown that reslizumab reduces the rate of exacerbations by approximately 50 percent compared with placebo [4,5]. Reslizumab is administered intravenously at four-week intervals. The US FDA has added a boxed warning because anaphylaxis occurred in 0.3 percent of treated patients. (See "Treatment of severe asthma in adolescents and adults", section on 'Reslizumab'.)
Safety of fluticasone-salmeterol combination therapy in asthma (March 2016)
In early studies, a small increase in asthma-related deaths associated with salmeterol led the US Food and Drug Administration to place a boxed warning on the use of salmeterol in asthma. While concerning, the number of events was small, and the magnitude of the risk was unclear. In addition, it could not be determined if the potential risk of salmeterol could be mitigated by combining it with an inhaled glucocorticoid. The safety of salmeterol in combination with fluticasone has been assessed in a multicenter trial, in which almost 12,000 adolescents and adults with persistent asthma were randomly assigned to take inhaled fluticasone or the combination of inhaled fluticasone-salmeterol (in a single inhaler) for 26 weeks . The rate of serious asthma-related adverse events was similar in the two groups, and no deaths occurred in either group. In addition, no difference was noted in the rate of asthma-related hospitalizations. Thus, for patients over age 12 who do not have a history of life-threatening asthma events, data are reassuring about the safety of fluticasone-salmeterol in a fixed-dose inhaler. (See "Beta agonists in asthma: Controversy regarding chronic use", section on 'Potential risk mitigation'.)
Combination inhaled glucocorticoid/long-acting beta agonists in patients with COPD and cardiovascular risk factors or disease (May 2016)
While the evidence has been generally reassuring about the safety of combination inhaled glucocorticoid plus long-acting beta agonist (ICS-LABA) inhalers in patients with chronic obstructive pulmonary disease (COPD), patients with known cardiovascular disease (CVD) were excluded from previous clinical trials. In the three-year randomized trial, Study to Understand Mortality and MorbidITy (SUMMIT), the effect of the fluticasone furoate-vilanterol combination inhaler was compared with the individual components and placebo in almost 17,000 patients with moderate COPD (FEV1 between 50 and 70 percent of predicted) and known or increased risk of CVD . Relative to placebo, the combination inhaler did not affect all-cause mortality or composite cardiovascular events. Thus, the presence of CVD should not affect the role of ICS-LABA inhalers in COPD. (See "Management of the patient with severe COPD and cardiovascular disease", section on 'Combination inhaled bronchodilator plus glucocorticoid'.)
Bronchoscopic therapies for severe emphysema (December 2015, Modified January 2016)
Two investigational devices, endobronchial valves and nitinol coils, can provide benefit by deflating areas of emphysematous lung that compromise function.
●The STELVIO trial included 68 patients with severe emphysema, favorable anatomy, and no evidence of collateral ventilation . Subjects were randomly assigned to receive bronchoscopic endobronchial valve (EBV) placement (average four per lobe) or standard medical care. After six months, the increases in lung function and exercise tolerance in the EBV group were greater than in the usual care group. However, serious adverse events occurred in the EBV group, including one death, six pneumothoraces, and the necessity for valve removal in seven patients, compared with five serious adverse events and no deaths in the control group.
●The REVOLENS trial included 100 patients with severe emphysema, of whom two-thirds had homogeneous emphysema, considered an unfavorable pattern for either surgery or endobronchial valve placement. Patients were randomly assigned to undergo endobronchial deployment of nitinol coils or usual care . The coil group had significant improvements in lung function and quality of life at 6 and 12 months. Pneumonia was the most frequent serious adverse event.
Taken together, these studies show that endobronchial valves or nitinol coils can improve lung function, exercise tolerance, and quality of life in carefully selected patients with severe emphysema who are willing to accept the associated risks. (See "Emerging therapies for COPD: Bronchoscopic treatment of emphysema", section on 'Endobronchial valves' and "Emerging therapies for COPD: Bronchoscopic treatment of emphysema", section on 'Coils'.)
Combination glycopyrrolate-indacaterol approved for use in COPD (December 2015)
A twice daily, dry powder inhaler containing glycopyrrolate-indacaterol (15.6 mcg-27.5 mcg) has been approved by the US Food and Drug Administration for the treatment of chronic obstructive pulmonary disease (COPD) . The United States preparation, which contains lower medication doses than the product approved in Europe and Japan (table 1), was examined in 2038 patients with moderate-to-severe COPD in parallel randomized trials . Significant benefits were noted in lung function, health-related quality of life, and dyspnea in the combination group compared with the individual components or placebo. (See "Management of stable chronic obstructive pulmonary disease", section on 'Combined therapy'.)
Simplified approach to acetylcysteine infusion for acetaminophen poisoning (April 2016)
The treatment of acetaminophen poisoning with acetylcysteine is sometimes complicated by nonallergic anaphylactic reactions (NAARs). The results of a large retrospective study, in addition to recent clinical experience, suggest that these reactions can be reduced by using a two-bag regimen instead of the traditional three-bag regimen described in the manufacturer’s package insert and most dosing references. In the study, NAARs occurred in 10 percent of the 389 patients treated with the standard regimen versus 4.3 percent of the 210 patients treated with a modified two-bag regimen . In both regimens, acetylcysteine was infused over 20 hours. While further study is needed to ensure the safety and effectiveness of this regimen, we believe this is a reasonable approach to treatment in adults and older adolescents with acetaminophen poisoning. (See "Acetaminophen (paracetamol) poisoning in adults: Treatment", section on 'Simplified 20 hour IV protocol'.)
Noninvasive ventilation for postoperative respiratory failure (April 2016)
Patient selection is critical for the success of noninvasive ventilation (NIV). The indications for NIV in medical patients with respiratory failure are well defined. However, the indications in patients with postoperative respiratory failure are less clear. The role of NIV was studied in a trial of nearly 300 spontaneously breathing patients who developed acute hypoxemic respiratory failure following abdominal surgery . Compared with patients treated with oxygen only, patients who received NIV had fewer reintubations, more ventilator-free days, and fewer healthcare-associated infections. The exclusion of patients requiring immediate reintubation and lower than expected rates of reintubation in general limits interpretation of this study. Although encouraging, these results do not support the routine administration of NIV for the treatment of respiratory failure in surgical patients. Clinicians should continue to individualize NIV and utilize it on a trial basis in this population. (See "Overview of the management of postoperative pulmonary complications", section on 'Postoperative respiratory failure'.)
High-flow oxygen following extubation (March 2016)
High-flow oxygen delivered via nasal cannula (HFNC) is being increasingly used in intensive care and high-dependency units since it can deliver high amounts of supplemental oxygen and a small amount of positive expiratory pressure. The efficacy of HFNC following extubation was studied in over 500 patients (mostly postoperative or neurologic) who had been mechanically ventilated for an average of only one to two days and considered at low risk of reintubation . Patients were randomly assigned to conventional low-flow oxygen or HFNC immediately following extubation. HFNC led to a reduction in the rate of reintubation and respiratory failure at 72 hours. These findings suggest that HFNC may be useful in patients who are at low risk for reintubation. However, the results may not apply to other patient populations, since critically ill medical patients and patients at high risk of reintubation were excluded from this study. (See "Extubation management", section on 'Oxygen'.)
Dexmedetomidine for agitation in ventilated patients (March 2016)
Dexmedetomidine, a centrally active alpha-2 agonist with anxiolytic, sedative, and analgesic effects but no deleterious effect on respiratory drive, is being increasingly used for treatment of agitation in mechanically ventilated patients. The randomized DahLIa trial evaluated use of dexmedetomidine in weaning patients with delirium from mechanical ventilation . In a mixed population of 71 intensive care unit (ICU) patients in whom agitated delirium was prohibiting extubation, dexmedetomidine plus standard sedation (mostly propofol) resulted in an increase in ventilator-free hours and reduced time to extubation, compared with placebo plus standard sedation. However, the trial was stopped early before the target enrollment needed for adequate power was reached. Although encouraging, these results are not definitive and further studies are needed prior to recommendations for the routine use of dexmedetomidine to facilitate extubation in patients with delirium. (See "Sedative-analgesic medications in critically ill adults: Properties, dosage regimens, and adverse effects", section on 'Dexmedetomidine'.)
New definitions of sepsis and septic shock (March 2016)
The 2016 guidelines from The Society of Critical Care Medicine and European Society of Intensive Care Medicine (SCCM/ESICM) propose a new definition for sepsis and septic shock [16-18]. Compared with older guidelines, a major change is the focus on using a multi-organ dysfunction score, the Sequential Organ Failure Assessment (SOFA) score, to help identify those at risk of dying from sepsis. Sepsis is now defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, where life-threatening organ dysfunction is identified by an increase of ≥2 points in the SOFA score; patients who fulfill these criteria have a predicted mortality of ≥10 percent. Patients with septic shock are defined as a subset of patients with sepsis who have profound circulatory, cellular, and metabolic abnormalities (ie, patients who, despite adequate fluid resuscitation, require vasopressors to maintain a mean arterial pressure ≥65 mmHg and have a lactate >2 mmol/L [>18 mg/dL]); these patients have a predicted mortality of ≥40 percent. The systemic inflammatory response syndrome (SIRS) criteria are no longer included in the definition. While not diagnostic, these definitions should help clinicians identify patients who are at increased risk of dying from sepsis. (See "Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis", section on 'Sepsis' and "Predictive scoring systems in the intensive care unit", section on 'Sequential (sepsis-related) Organ Failure Assessment (SOFA)'.)
Identification of early sepsis (March 2016)
The identification of early sepsis is critical for the prevention of sepsis-related death. A task force from the 2016 Society of Critical Care Medicine and European Society of Intensive Care Medicine (SCCM/ESICM) has described a new assessment score for patients outside the intensive care unit (ICU) as a way to facilitate the identification of patients potentially at risk of dying from sepsis [16-18]. The quick Sequential Organ Failure Assessment score (qSOFA) can be easily calculated at the bedside; it comprises only three components, each worth 1 point: respiratory rate ≥22/minute, altered mentation, and systolic blood pressure ≤100 mmHg. Although this tool does not detect early sepsis, a score ≥2 was associated with poor outcomes in patients with suspected infection, and may prompt the clinician to consider sepsis so that they can monitor and/or or investigate accordingly. While promising, qSOFA requires prospective validation before it can be routinely used to identify patients with early sepsis outside of the ICU. (See "Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis", section on 'Identification of early sepsis' and "Predictive scoring systems in the intensive care unit", section on 'Sequential (sepsis-related) Organ Failure Assessment (SOFA)'.)
Nutrition guidelines in critically ill adults (March 2016)
Guidelines for nutritional support in critically ill adult patients were published by the Society of Critical Care Medicine and the American Society for Parenteral and Enteral Nutrition . Compared with earlier versions of the guidelines, emphasis is placed upon appropriate assessment of nutritional status in all critically ill patients using indirect calorimetry or published equations, as well as the early (within 48 hours of admission) administration of trophic enteral nutrition (EN) in adequately nourished patients using high-protein formulations. Supplementation of EN with glutamine, omega-3 fish oils, or antioxidants is discouraged. Parenteral nutrition is reserved for those who are unable to be fed adequately enterally and can be delayed for up to 10 days in those who are adequately nourished. Further detailed recommendations are made for specialized populations of critically ill patients including those who are inadequately nourished, postoperative patients, patients who are obese, as well as patients with acute pancreatitis, renal failure, liver failure, and sepsis. Notably, these guidelines only considered studies that were published up until 2014, and the overall quality of the evidence was low. (See "Nutrition support in critically ill patients: An overview", section on 'Introduction'.)
Detection and outcomes in acute respiratory distress syndrome (March 2016)
Little is known about the global incidence of acute respiratory distress syndrome (ARDS) in adults and whether best practices are adhered to when treating patients with ARDS in the intensive care unit (ICU). In a multicenter, international, prospective, cohort study of nearly 30,000 ICU patients, ARDS was responsible for 10 percent of admissions and for 23 of patients who were mechanically ventilated . Despite published definitions of ARDS and known benefits of low tidal volume ventilation (6 to 8 mL/kg ideal body weight; the standard of care), clinicians demonstrated poor recognition of the disorder, particularly when it was mild, and less than two-thirds of patients received the recommended tidal volume. Mortality remained high, ranging from 35 (mild ARDS) to 46 (severe ARDS) percent. Thus, clinicians appear to under-recognize and use suboptimal ventilatory strategies in patients with ARDS, a disease that continues to be associated with a high disease burden in the ICU and significant mortality. (See "Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults", section on 'Epidemiology'.)
FDA approval of sugammadex for reversal of neuromuscular blockade (January 2016)
Neuromuscular blockade due to rocuronium (or vecuronium) can be rapidly reversed with sugammadex, a novel chelating agent. Several trials have demonstrated that, compared with neostigmine, administration of sugammadex at the end of surgery results in faster complete reversal of neuromuscular blockade due to rocuronium or vecuronium, with shorter time to discharge from the operating room. Use of rocuronium with sugammadex reversal may be especially useful for potentially difficult or rapid sequence intubations, since sugammadex also results in a faster recovery of neuromuscular function compared with spontaneous recovery after succinylcholine administration. Sugammadex has been available in many countries for several years and was approved by the US Food and Drug Administration (FDA) in December 2015 . (See "Induction of general anesthesia", section on 'Sugammadex' and "Management of the difficult airway for general anesthesia" and "Overview of complications occurring in the post-anesthesia care unit" and "Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults".)
Venous thromboembolism risk with central versus peripheral insertion of central venous catheters (January 2016)
There is accumulating evidence that peripherally-inserted central venous catheters (PICCs) are associated with a greater risk for upper extremity deep vein thrombosis (UEDVT) compared with centrally-inserted central venous catheters (CICCs). The Medical Inpatients and Thrombosis (MITH) Study evaluated catheter use in 299 venous thromboembolism cases compared with controls without venous thromboembolism at a single institution . Central catheter use was associated with a 14-fold increased risk for UEDVT, without a significantly increased risk for pulmonary embolism. PICCs were associated with a higher cumulative risk compared with CICCs (8.1 versus 4.8 per 1000 admissions). Given the higher risk for UEDVT with PICCs, we generally avoid them in patients for whom maintaining vascular patency and integrity for long-term vascular access options (eg, future hemodialysis access) is essential. (See "Catheter-related upper extremity venous thrombosis", section on 'Peripheral versus central insertion' and "Overview of central venous access".)
Reversal agent for factor Xa inhibitors (November 2015)
Lack of reversal agents for the direct oral anticoagulants has been a concern. Andexanet alfa is a recombinant protein designed to reverse factor Xa inhibitors by binding to the drugs and sequestering them away from endogenous factor Xa. In a randomized trial in healthy volunteers, an andexanet bolus reduced anti-factor Xa activity by 94 percent and 92 percent for volunteers taking apixaban or rivaroxaban, respectively, compared with reductions of 21 and 18 percent for a placebo bolus . A study evaluating andexanet efficacy in patients with factor Xa inhibitor-associated bleeding is ongoing. (See "Management of bleeding in patients receiving direct oral anticoagulants", section on 'Antidotes under development'.)
INTERSTITIAL LUNG DISEASE
Possible delayed response to pirfenidone therapy in idiopathic pulmonary fibrosis (May 2016)
In patients with idiopathic pulmonary fibrosis (IPF), serial measurement of forced vital capacity (FVC) demonstrates substantial variability over time, making it difficult to analyze treatment responses and select subsequent treatment. In a follow-up to the original trials of pirfenidone in IPF, 34 subjects on pirfenidone and 68 subjects on placebo who experienced a ≥10 percent decline in FVC in the first three or six months were reassessed six months later . Fewer subjects in the pirfenidone group experienced a further ≥10 percent decline in FVC or death in the following six months compared with the placebo group (2/34 versus 19/68, respectively). While the numbers are small, this study suggests that continuing pirfenidone may be of benefit despite initial evidence of disease progression. (See "Treatment of idiopathic pulmonary fibrosis", section on 'Pirfenidone'.)
FDA approval for alectinib in crizotinib-resistant ALK-positive NSCLC (December 2015)
Alectinib was recently approved by the US Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant of crizotinib. This approval was based on the results of two single-arm phase II studies in patients with crizotinib-resistant ALK-positive, locally advanced or metastatic NSCLC that suggested a 50 percent response rate to alectinib [25,26]. Among patients with brain metastases, the majority of whom had received prior radiation therapy, the objective central nervous system (CNS) response rate was 57 percent in one study and 75 percent in the other, and the median duration of CNS response was 10 and 11 months, respectively. These data support the use of alectinib in patients with crizotinib refractory ALK-positive NSCLC and demonstrate its efficacy for managing both systemic and brain metastases. (See "Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Alectinib'.)
Zika virus and tissue/gamete donation (March 2016)
Zika virus has been detected in a number of tissues and body fluids. To avoid possible transmission of Zika virus infection, the US Food and Drug Administration (FDA) has issued donor deferral recommendations for hematopoietic stem cells, tissues, and donor sperm or eggs; the recommendations do not apply to solid organs . Living donors with Zika virus infection or relevant epidemiologic exposure (residence in or travel to an area where mosquito-borne transmission of Zika virus infection has been reported, or unprotected sexual contact with a person who meets these criteria) should be considered ineligible for donation for six months. Deceased donors with Zika virus infection in the preceding six months should also be considered ineligible. The deferral period recommended by the FDA for blood donors with risk factors for Zika virus infection remains at four weeks. (See "Zika virus infection: An overview", section on 'Blood/tissue donation'.)
Small versus large chest tubes for malignant effusion pleurodesis (January 2016)
The optimal diameter chest tube for malignant effusion pleurodesis is uncertain. Smaller diameter tubes are assumed to be more comfortable, but larger diameter tubes may provide better drainage. Nonrandomized studies suggest there is no difference. A multicenter trial compared pleurodesis failure rates and pain scores among 100 patients treated using either a small (12 Fr) or large (24 Fr) chest tube . At three months of follow-up, pleurodesis failure rates were not statistically different for smaller versus larger tubes (30 versus 24 percent). Pain scores were slightly lower for patients receiving smaller chest tubes. The small sample size for the tube diameter comparison may have limited the ability to detect a difference in pleurodesis failure rates, if one existed. Until a larger trial is available, we continue to use a smaller bore catheter (8 to 18 Fr) chest tube placed under imaging guidance for initial malignant effusion pleurodesis. (See "Placement and management of thoracostomy tubes", section on 'Malignant effusion' and "Management of malignant pleural effusions", section on 'Chest tube size'.)
PULMONARY VASCULAR DISEASE
Updated guidelines for the treatment of venous thromboembolism (March 2016)
The American College of Chest Physicians (ACCP) has published new guidelines on antithrombotic therapy for venous thromboembolic (VTE) disease that include guidance on choice of anticoagulant, indications for extended anticoagulation, and indications for thrombolytic therapy in patients with acute pulmonary embolism (PE) . In addition to a preference for direct oral anticoagulants for the treatment of VTE, the ACCP suggests extending anticoagulation beyond three months (ie, no scheduled stop date) in patients with unprovoked VTE or active cancer. For most patients with small subsegmental pulmonary embolism (SSPE), anticoagulation is suggested; however, clinical surveillance with lower extremity Doppler ultrasound may be appropriate for select patients with a low burden of SSPE who have no evidence of thrombus elsewhere and in whom the risk of recurrence is low. The guidelines suggest administration of systemic thrombolytic therapy, rather than catheter-directed thrombolysis (CDT), for patients with hemodynamically-significant PE; CDT may be appropriate for those who fail systemic thrombolysis or who are at high risk of bleeding. (See "Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis", section on 'Indications' and "Venous thromboembolism: Anticoagulation after initial management", section on 'Selection of agent' and "Rationale and indications for indefinite anticoagulation in patients with venous thromboembolism", section on 'Patients likely to benefit' and "Overview of the treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Patients with subsegmental PE'.)
Agent selection for anticoagulation in venous thromboembolism (March 2016)
Guidelines for the treatment of acute venous thromboembolism (VTE) were issued by The American College of Chest Physicians (ACCP) . Compared with earlier versions of the guidelines, the direct oral anticoagulants (DOACs) apixaban, edoxaban, rivaroxaban, or dabigatran are now the preferred agents for long-term anticoagulation in patients who are not pregnant and do not have active cancer or severe renal insufficiency. This preference was based upon randomized trials that consistently reported similar efficacy, a lower bleeding risk, and improved convenience when compared with warfarin. We agree with this preference for DOACs in patients with acute VTE, understanding that choosing among anticoagulants frequently depends upon availability and cost as well as patient comorbidities and preferences. (See "Venous thromboembolism: Anticoagulation after initial management", section on 'Selection of agent'.)
Estimation of pulmonary artery pressure by echocardiography (February 2016)
The accuracy of echocardiographic estimation of pulmonary artery systolic pressure has been questioned. While some studies have reported that echocardiographic estimates and right heart catheterization results correlate strongly, other studies have found only weak correlations. Suboptimal echocardiogram quality is a likely cause of these discrepant results. In a retrospective study of 307 echocardiograms in patients with advanced lung disease or pulmonary arterial hypertension, only 61 percent of studies were deemed sufficient for estimation of pulmonary artery pressure . For interpretable studies, identification of pulmonary hypertension by expert readers was excellent (area under the curve 0.97). We suggest adherence to specific quality metrics for acquisition and interpretation of echocardiograms to optimize pulmonary artery pressure estimation, with confirmation of pressures by invasive right heart catheterization as clinically indicated. (See "Echocardiographic assessment of the right heart", section on 'Estimation of pulmonary artery systolic pressure'.)
Oral prostacyclin receptor agonist in pulmonary arterial hypertension (January 2016)
Prostanoids are highly effective agents for group 1 pulmonary arterial hypertension (PAH), but have only been available in parenteral formulations and are typically reserved for those with the most severe disease (World Health Organization [WHO] class IV). Less severe PAH (WHO class II or III) is usually treated with oral non-prostanoid pulmonary vasodilators. Selexipag is a selective prostacyclin receptor agonist, with actions similar to prostanoids, which is now available in an oral formulation and was evaluated in a randomized trial in 1156 patients with group 1 PAH, WHO class II or III . Selexipag was associated with a significant benefit compared with placebo, which was largely driven by a reduction in hospitalizations and disease progression, rather than by improved survival. Adverse effects were mostly mild and consistent with the known side effects of prostanoids, including headache, diarrhea, nausea, and jaw pain. We consider selexipag as a useful alternative to other oral agents for the treatment of patients with group 1 PAH, WHO class II or III. Parenteral prostanoids should remain the mainstay of therapy for WHO class IV disease. (See "Treatment of pulmonary hypertension in adults", section on 'Selexipag'.)
Warfarin associated with worse survival in systemic sclerosis-associated pulmonary arterial hypertension (December 2015)
Early studies suggested a possible mortality benefit for anticoagulation with warfarin in patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). However, a post-hoc analysis of a PAH registry study reported a trend towards worse survival in patients with SSc-PAH who received anticoagulant therapy compared with those not receiving anticoagulant therapy . A subsequent analysis of a separate registry of PAH patients also reported an increased mortality in the same population, even after adjustment for confounders including disease severity . Based on findings of these studies, we suggest that anticoagulant therapy not be administered to patients with systemic sclerosis-associated PAH. (See "Treatment of pulmonary hypertension in adults", section on 'Anticoagulation'.)
Clinical practice guideline for chronic insomnia in adults (May 2016)
The American College of Physicians has released a new clinical practice guideline for the management of chronic insomnia in adults . The guideline recommends that all patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder. The guideline suggests that clinicians use a shared decision-making approach, including discussion of benefits, harms, and costs of short-term use of medications, to decide whether to add medication to CBT-I in patients with persistent symptoms. This approach is consistent with our preference for behavioral therapy over medication in most patients with chronic insomnia, particularly in older adults and patients with organ dysfunction, who are at increased risk for side effects from sedative-hypnotic drugs. (See "Treatment of insomnia", section on 'General approach'.)
Racial and ethnic disparities in sleep duration and quality (February 2016)
Survey-based studies have consistently found that black Americans and other racial and ethnic minorities report higher rates of insufficient sleep and poor sleep quality compared with white Americans. These disparities were confirmed in a recent population-based study in which nearly 500 individuals completed seven nights of wrist actigraphy monitoring . Black Americans had significantly shorter mean sleep duration compared with white Americans (6.7 versus 7.5 hours), independent of age, gender, education, work status, and medical comorbidities. Multiple indicators of sleep quality were also worse in blacks and other racial and ethnic minorities. Further studies are needed to better understand the causes of these disparities, as short sleep duration has been associated with a wide range of adverse health outcomes, including cardiovascular morbidity and all-cause mortality. (See "Sleep insufficiency: Definition, consequences, and management", section on 'Epidemiology'.)
Respiratory effects of suvorexant in patients with obstructive sleep apnea (February 2016)
Limited available data suggest that suvorexant, an orexin receptor antagonist recently approved for treatment of insomnia, has the potential to worsen respiration during sleep in vulnerable patients. In a sleep laboratory study in which 26 adults with mild to moderate obstructive sleep apnea (OSA) were given 40 mg of suvorexant or placebo for four consecutive nights, the apnea-hypopnea index (AHI) increased by a mean of 2.7 events per hour after multiple doses of suvorexant . The AHI rose by 5 or more in eight patients (range 5 to 20), an increase that is generally considered to be clinically significant. These data suggest that suvorexant, like other sedatives, should be used cautiously in patients with OSA and other sleep-related breathing disorders. (See "Treatment of insomnia", section on 'Adverse effects of orexin antagonists'.)
Online versus face-to-face cognitive behavioral therapy for insomnia (February 2016)
Telephone or online delivery of cognitive behavioral therapy for insomnia (CBT-I) has been proposed as an alternative to face-to-face delivery, which could help overcome some of the access barriers to traditional therapy. In a trial comparing face-to-face and guided online CBT-I with a wait-list control in 90 patients with insomnia, both delivery methods performed better than the wait-list control, but face-to-face CBT-I was associated with larger treatment effects and better depression and anxiety outcomes than online delivery . These results, along with those of other small trials, suggest that online CBT-I may be an alternative to traditional CBT-I in patients with limited access to in-person therapy, particularly those without comorbid mood disorders. (See "Treatment of insomnia", section on 'Cognitive behavioral therapy'.)
Mandibular advancement devices lower blood pressure in sleep apnea (December 2015)
Improved blood pressure control is a benefit associated with continuous positive airway pressure (CPAP) treatment in patients with obstructive sleep apnea (OSA) and hypertension. However, it is unclear whether therapeutic modalities other than CPAP result in the same benefit. One meta-analysis of 51 studies of patients with hypertension and OSA reported that compared with patients on placebo or not receiving therapy, mandibular advancement devices (MADs) were associated with a significant reduction in systolic and diastolic blood pressure . The level of reduction was similar to that reported in patients treated with CPAP. While this study does not alter the indications for either therapy, it suggests that patients with OSA who are treated with MADs may derive similar positive effects on blood pressure control as those treated with CPAP. (See "Obstructive sleep apnea and cardiovascular disease", section on 'Impact of treatment'.)
OTHER PULMONARY MEDICINE
New ACCP guidelines for the treatment of unexplained chronic cough (March 2016)
The American College of Chest Physicians has published new guidelines for the treatment of unexplained chronic cough (defined as cough >8 weeks' duration that is unexplained after systematic investigation and treatment) . The guidelines newly include a suggestion for a therapeutic trial of gabapentin (a central inhibitor of neurotransmitter release). Due to the known adverse effects of gabapentin (eg, somnolence, weakness, diarrhea, and nausea), the initial dose should be 300 mg daily, which can be gradually increased as tolerated to a maximum dose of 900 mg twice daily. (See "Treatment of subacute and chronic cough in adults", section on 'Gabapentin and pregabalin'.)
Treatment of unexplained chronic cough with pregabalin (March 2016)
Like gabapentin, pregabalin is thought to act centrally to inhibit neurotransmitter release. Evidence for its use in chronic cough comes from a randomized trial in which 40 adults with chronic refractory cough were assigned to take pregabalin daily or placebo combined with speech pathology treatment for 14 weeks . Baseline cough frequency was 24 coughs/hour in both groups; spirometry was normal. Both groups experienced a reduction in cough severity and cough frequency, and improvements in cough-related quality of life (QOL). The pregabalin group experienced greater improvement in cough severity and QOL. Adverse effects in the pregabalin group included dizziness in 45 percent and cognitive changes in 30 percent, although these did not lead to discontinuation of the study drug. Four weeks after withdrawal of study medication, there was no deterioration in symptom control. To minimize sedation and dizziness, pregabalin is initiated at a low dose and gradually increased as tolerated over a week. Of note, the American College of Chest Physicians (ACCP) guidelines do not include pregabalin because this study was published after the guidelines were prepared. (See "Treatment of subacute and chronic cough in adults", section on 'Gabapentin and pregabalin'.)
Nontuberculous mycobacteria in patients with cystic fibrosis (February 2016)
Nontuberculous mycobacteria (NTM) are in the sputum of up to 20 percent of patients with cystic fibrosis (CF), and some of these patients develop progressive NTM pulmonary disease (NTM-PD). New guidelines provide recommendations for the screening, diagnosis, and management of NTM in CF patients . Annual screening of sputum is recommended for all expectorating patients. Patients with persistently positive results or symptoms suggesting NTM-PD should have a full evaluation including high-resolution computed tomography (HRCT) and sometimes bronchoscopy to determine if they meet criteria for NTM pulmonary disease (table 2). For any patient on chronic azithromycin therapy suspected of NTM infection, azithromycin should be stopped temporarily pending further diagnostic evaluation, to reduce the risk of inducing resistance because of monotherapy. (See "Cystic fibrosis: Antibiotic therapy for lung disease", section on 'Nontuberculous mycobacteria'.)
IDSA guidelines on the management of candidiasis (January 2016)
The Infectious Diseases Society of America released updated guidelines for the management of patients with candidiasis . A substantial change compared with previous versions is the preference for echinocandins (anidulafungin, caspofungin, micafungin) as first-line therapy for candidemia and invasive candidiasis. As an example, for both nonneutropenic and neutropenic patients with candidemia, an echinocandin is the preferred choice for initial therapy (table 3). This change is due to an increase in fluconazole-resistant Candida infections, the favorable safety profile of the echinocandins, and accumulating efficacy data and clinical experience to support the echinocandins. Important exceptions include Candida central nervous system, eye, and urinary tract infections, for which other antifungals are preferred. (See "Treatment of candidemia and invasive candidiasis in adults", section on 'Nonneutropenic patients'.)
Adjuvanted influenza vaccine approved for elderly adults in the United States (November 2015)
There has been interest in using adjuvants in influenza vaccines in elderly individuals, who have reduced immune responses to influenza vaccines; adjuvants are substances that amplify the immune response to an antigen. In November 2015, an adjuvanted trivalent inactivated influenza vaccine (Fluad) was approved for use in individuals ≥65 years of age in the United States . It is the first adjuvanted seasonal influenza vaccine to be approved in the United States, but it has been approved already in >35 other countries. The vaccine is formulated with the adjuvant MF59, an oil-in-water emulsion of squalene oil. Studies have shown that the MF59-adjuvanted vaccine has comparable  or higher immunogenicity compared with unadjuvanted vaccines [44-46]. Until further data are available, we continue to suggest the non-adjuvanted high-dose inactivated vaccine for individuals ≥65 years of age. (See "Seasonal influenza vaccination in adults", section on 'Adjuvanted vaccine' and "Seasonal influenza vaccination in adults", section on 'Vaccine formulations'.)
Statins and influenza vaccine immunogenicity and effectiveness (November 2015)
Statins are used commonly in older adults with hyperlipidemia and are known to have immunomodulatory effects, which could affect vaccine responses. In an observational study conducted in the context of a randomized trial that evaluated influenza vaccines in individuals >65 years of age, hemagglutination inhibition (HAI) geometric mean titers to various influenza strains were substantially lower in those receiving chronic statin therapy than in those not receiving it . In addition, in the adjusted analysis of a large retrospective cohort study, statin use was associated with reduced influenza vaccine effectiveness against medically attended acute respiratory illness . The observed associations between statin use and vaccine effectiveness could be due to confounding, as patients receiving statins are likely to be at differing baseline risk of influenza from those not receiving statins. Although these studies raise the possibility that older patients receiving statins are less likely to be protected by the influenza vaccine, such individuals should still receive statins, when indicated, as well as an influenza vaccine annually. (See "Seasonal influenza vaccination in adults", section on 'Efficacy'.)
- Virchow JC, Backer V, Kuna P, et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. JAMA 2016; 315:1715.
- Kapadia CR, Nebesio TD, Myers SE, et al. Endocrine Effects of Inhaled Corticosteroids in Children. JAMA Pediatr 2016; 170:163.
- US Food and Drug Administration. Reslizumab (Cinqair) prescribing information. http://www.cinqair.com/pdf/PrescribingInformation.pdf (Accessed on March 28, 2016).
- Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184:1125.
- Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3:355.
- Stempel DA, Raphiou IH, Kral KM, et al. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. N Engl J Med 2016.
- Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016; 387:1817.
- Klooster K, ten Hacken NH, Hartman JE, et al. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J Med 2015; 373:2325.
- Deslée G, Mal H, Dutau H, et al. Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial. JAMA 2016; 315:175.
- Utibron neohaler prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/utibron.pdf (Accessed on November 02, 2015).
- Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2015; 192:1068.
- Wong A, Graudins A. Simplification of the standard three-bag intravenous acetylcysteine regimen for paracetamol poisoning results in a lower incidence of adverse drug reactions. Clin Toxicol (Phila) 2016; 54:115.
- Jaber S, Lescot T, Futier E, et al. Effect of Noninvasive Ventilation on Tracheal Reintubation Among Patients With Hypoxemic Respiratory Failure Following Abdominal Surgery: A Randomized Clinical Trial. JAMA 2016; 315:1345.
- Hernández G, Vaquero C, González P, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. JAMA 2016; 315:1354.
- Reade MC, Eastwood GM, Bellomo R, et al. Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium: A Randomized Clinical Trial. JAMA 2016; 315:1460.
- Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801.
- Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:762.
- Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:775.
- McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2016; 40:159.
- Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA 2016; 315:788.
- FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery. www.fda.gov/NewsEvents/Newsroom/PressAnouncements/ucm477512.htm (Accessed on January 07, 2016).
- Winters JP, Callas PW, Cushman M, et al. Central venous catheters and upper extremity deep vein thrombosis in medical inpatients: the Medical Inpatients and Thrombosis (MITH) Study. J Thromb Haemost 2015; 13:2155.
- Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015; 373:2413.
- Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 2016; 71:429.
- Ou SH, Ahn JS, De Petris L, et al. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol 2016; 34:661.
- Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016; 17:234.
- US Food and Drug Administration. Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products: Guidance for Industry, March 2016. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM488582.pdf (Accessed on March 07, 2016).
- Rahman NM, Pepperell J, Rehal S, et al. Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. JAMA 2015; 314:2641.
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149:315.
- Amsallem M, Sternbach JM, Adigopula S, et al. Addressing the Controversy of Estimating Pulmonary Arterial Pressure by Echocardiography. J Am Soc Echocardiogr 2016; 29:93.
- Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2015; 373:2522.
- Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129:57.
- Preston IR, Roberts KE, Miller DP, et al. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation 2015; 132:2403.
- Qaseem A, Kansagara D, Forciea MA, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med 2016.
- Carnethon MR, De Chavez PJ, Zee PC, et al. Disparities in sleep characteristics by race/ethnicity in a population-based sample: Chicago Area Sleep Study. Sleep Med 2016; 18:50.
- Sun H, Palcza J, Card D, et al. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. J Clin Sleep Med 2016; 12:9.
- Lancee J, van Straten A, Morina N, et al. Guided Online or Face-to-Face Cognitive Behavioral Treatment for Insomnia: A Randomized Wait-List Controlled Trial. Sleep 2016; 39:183.
- Bratton DJ, Gaisl T, Wons AM, Kohler M. CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. JAMA 2015; 314:2280.
- Gibson P, Wang G, McGarvey L, et al. Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report. Chest 2016; 149:27.
- Vertigan AE, Kapela SL, Ryan NM, et al. Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial. Chest 2016; 149:639.
- Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71 Suppl 1:i1.
- Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.
- FDA news release. FDA approves first seasonal influenza vaccine containing an adjuvant. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474295.htm (Accessed on November 25, 2015).
- Black S. Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults. Vaccine 2015; 33 Suppl 2:B3.
- De Donato S, Granoff D, Minutello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999; 17:3094.
- O'Hagan DT, Rappuoli R, De Gregorio E, et al. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 2011; 10:447.
- Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of Statins on Influenza Vaccine Response in Elderly Individuals. J Infect Dis 2016; 213:1224.
- Omer SB, Phadke VK, Bednarczyk RA, et al. Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. J Infect Dis 2016; 213:1216.